TY - JOUR
T1 - DNA repair capacity correlates with standardized uptake values from 18F-fluorodeoxyglucose positron emission tomography/CT in patients with advanced non–small-cell lung cancer
AU - Jiang, Xin (Eric)
AU - Xu, Ting
AU - Wei, Qingyi
AU - Li, Peng
AU - Gomez, Daniel R.
AU - Court, Laurence E.
AU - Liao, Zhongxing
N1 - Funding Information:
This work was supported by Grants No. R01 ES 011740 and CA 131274 (Q.W.) from the U.S. National Institutes of Health, and Cancer Center Core Grant No. P30 CA 016672 (MD Anderson Cancer Center).
Publisher Copyright:
© 2018 Chinese Medical Association
PY - 2018/6
Y1 - 2018/6
N2 - Objective: The DNA repair capacity (DRC) of tumor cells is an important contributor to resistance to radiation and platinum-based drugs. Because DRC may be affected by tumor cell metabolism, we measured DRC in lymphocytes from patients with non–small-cell lung cancer (NSCLC) and compared the findings with the maximum standardized uptake value (SUVmax) on18F-fluorodeoxyglucose positron emission tomography (FDG PET) after (chemo)radiation therapy. Methods: This study included 151 patients with stage IA-IV NSCLC who had FDG PET at a single institution and donated blood samples before chemotherapy. We assessed the correlation of DRC, measured in peripheral T lymphocytes by a host-cell reactivation assay with SUVmax and their associations with overall survival (OS) time by hazards ratios calculated with a Cox proportional hazards regression model. Results: SUVmax of the primary tumor at diagnosis was inversely associated with lymphocyte DRC (r = −0.175, P = 0.032), particularly among patients with advanced disease (r = −0.218, P = 0.015). However, ΔSUVmax of primary tumor was not significantly associated with DRC (r = 0.005, P = 0.968). SUVmax of regional lymph nodes at diagnosis (r = −0.307, P = 0.0008) and after (chemo)radiation treatment (r = −0.329, P = 0.034) and SUVmax of the primary tumor after (chemo)radiation treatment (r = −0.253, P = 0.045) were also inversely associated with OS time. Conclusion: DRC was inversely associated with primary tumor SUVmax before treatment but not with ΔSUVmax after (chemo)radiation.
AB - Objective: The DNA repair capacity (DRC) of tumor cells is an important contributor to resistance to radiation and platinum-based drugs. Because DRC may be affected by tumor cell metabolism, we measured DRC in lymphocytes from patients with non–small-cell lung cancer (NSCLC) and compared the findings with the maximum standardized uptake value (SUVmax) on18F-fluorodeoxyglucose positron emission tomography (FDG PET) after (chemo)radiation therapy. Methods: This study included 151 patients with stage IA-IV NSCLC who had FDG PET at a single institution and donated blood samples before chemotherapy. We assessed the correlation of DRC, measured in peripheral T lymphocytes by a host-cell reactivation assay with SUVmax and their associations with overall survival (OS) time by hazards ratios calculated with a Cox proportional hazards regression model. Results: SUVmax of the primary tumor at diagnosis was inversely associated with lymphocyte DRC (r = −0.175, P = 0.032), particularly among patients with advanced disease (r = −0.218, P = 0.015). However, ΔSUVmax of primary tumor was not significantly associated with DRC (r = 0.005, P = 0.968). SUVmax of regional lymph nodes at diagnosis (r = −0.307, P = 0.0008) and after (chemo)radiation treatment (r = −0.329, P = 0.034) and SUVmax of the primary tumor after (chemo)radiation treatment (r = −0.253, P = 0.045) were also inversely associated with OS time. Conclusion: DRC was inversely associated with primary tumor SUVmax before treatment but not with ΔSUVmax after (chemo)radiation.
KW - DNA repair capacity
KW - F-fluorodeoxyglucose positron emission tomography
KW - Non–small-cell lung cancer
KW - Outcome
KW - Standardized uptake value
UR - http://www.scopus.com/inward/record.url?scp=85109085389&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85109085389&partnerID=8YFLogxK
U2 - 10.1016/j.cdtm.2018.05.003
DO - 10.1016/j.cdtm.2018.05.003
M3 - Article
C2 - 29988954
AN - SCOPUS:85109085389
SN - 2095-882X
VL - 4
SP - 109
EP - 116
JO - Chronic Diseases and Translational Medicine
JF - Chronic Diseases and Translational Medicine
IS - 2
ER -